RE:RE:Meanwhile Verte 's IR department Stockfshr... here are some other points to consider:
- Philip has been telling us since April 2021 that a deal was eminent. And that the stock price would jump as a consequence
- Chris Barnes has also been telling us that once TSX listing achieved, institutional buyers and volume would pick up. Institutionals were also waiting for the deal to be announced
- Difficult to see how more botched the last few weeks have been managed. Despite all the good news (deal,clinical results continuing to be positive, Vertex being in trouble, etc...) stock price and volume stagnant. As if nothing happened
- certaining legitimate questions as to whether we have the right people to manage a public company, create shareholder value (for all of us) and follow through on execution in a timely manner
- if they couldn't manage the last few weeks properly, how do you think they'll do in creating "go to market" conditions?
= marketing
= reaching out to health care groups and governments
= securing manufacturing capacity (they say they have it, but no manufacturing group is on standby for months / years)
= defining training materials / standardized procedure
= training the surgeons
= distribution
= hiring / recruitments for folks to do all this stuff (I'm estimating they'll need approx 400 people)
= all this in place by 2026!
of course, one comment I often hear is to sell if I'm not happy. But the volume won't allow it. If several retail investors decide to sell sizable positions, price will crater more than now.
So I certainly understand folks being unhappy. And yes, most of it rests on the shoulders of management. And no, doesn't look good for the future unless we get bought out or Evotec does the heavy lifting.